MYD88 and cancer: Recent studies have shown that TLR4/MyD88-mediated COX-2/PGE2 signaling in tumor stromal cells promotes cancer progression through multiple mechanisms: inhibiting apoptosis, enhancing angiogenesis, and modulating immune function (37, 43).